Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-sequencing assay to identify changed gene expression in lung adenocarcinoma (LUAD) cells before and after osimertinib resistance

ABSTRACT: The H1975 osimertinib resistant (H1975 OR) cell lines were successfully established by subjecting parental H1975 cells to a gradually increasing concentration of osimertinib up to 1μM for a duration exceeding 2 months. In order to investigate the molecular alterations associated with osimertinib resistance, we analyzed the transcriptional profiling of parental H1975 cells and H1975 OR cells by RNA sequencing.

ORGANISM(S): Homo sapiens

PROVIDER: GSE272162 | GEO | 2024/08/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Osimertinib resistant cells of H1975

Project description:Osimertinib resistant cells of H1975

| PRJNA767314 | ENA

Gene expression data in the human non-small cell lung cancer cell line NCI-H1975 and osimertinib-resistant OR1 and OR2 cells

Project description:Osimertinib, a third-generation EGFR-TKI, has applied to non-small cell lung cancer harboring activated EGFR mutation with or without T790M. However, the appearance of tumors resistant to osimertinib has been reported. We established and characterized osimertinib-resistant cells derived from NCI-H1975 cells harboring activating EGFR and T790M mutation.

2022-04-28 | GSE201608 | GEO

Expression data of osimertinib tolerant H1975 cells

Project description:Expression data of osimertinib tolerant H1975 cells

| PRJNA827146 | ENA

Disclosing potential therapeutic targets associated with Osimertinib resistance in non-small cell lung cancer cell line H1975

Project description:Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is a highly effective and valuable treatment option for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations, like T790M. However, acquired resistance ultimately limits its clinical application. In this study, we constructed H1975/OSI cell lines and utilized potentially complementary transcriptomic and proteomic techniques, which may provide insight into the intricately complex molecular mechanisms, to reveal potential therapeutic targets associated with Osimertinib resistance. Uni-omics and multi-omics analyses were conducted on the transcriptomic and proteomic (4D label-free) expression profiles, which involved differential expression analysis, GO functional annotation and KEGG pathway enrichment analysis, correlation analysis of transcription factors, PPI network and Cytoscape analysis. We highlighted multiple signaling pathways and eleven hub-genes, including NOP56, DDX21, PDCD11, CCNB1, TOP21, KPNA2, DDX5, EFTUD2, BRCA1, LMNB1 and HIF1A, that may be the key to overcoming resistance. Further validation of these targets and molecules in preclinical and clinical studies could lead to the development of new and more effective treatment options for H1975-resistant patients.

2024-08-05 | GSE236654 | GEO

RNA-sequencing assay to identify changed gene expression in lung adenocarcinoma (LUAD) cells before and after osimertinib resistance

Project description:RNA-sequencing assay to identify changed gene expression in lung adenocarcinoma (LUAD) cells before and after osimertinib resistance

| PRJNA1135239 | ENA

Revealing the underlying regulatory mechanism of LINC00313 in Osimertinib-resistant NSCLC cells by ceRNA network analysis

Project description:In this study, RNA-sequencing technology was employed to identify the differentially expressed lncRNAs (DE-lncRNAs) and mRNAs (DE-mRNAs) between H1975 and H1975OR. Based on the starbase 2.0 database, the potential targeting relationships between DE-lncRNAs and DE-mRNAs were predicted and identified to construct the ceRNA networks. Subsequently, functional and pathway enrichment analysis were carried for target DE-mRNAs to obtain functional pathways associated with Osimertinib resistance and potential drug resistance-related DE-mRNAs. Besides, the expression of LINC00313 and COL1A1 was validated by q-Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). Finally, the activation of PI3K/Akt pathway was proved by immunohistochemistry staining.

2023-03-31 | GSE228049 | GEO

Circ101093 regulated proteins in Lung carcinoma (LUAD) cells.

Project description:Circ101093 was knocked down in A549 LUAD cell lines, and overexpressed in H1975 LUAD cell lines. Then, downregulated proteins in A549 cell lines and upregulated proteins in H1975 cell lines were analyzed.

2022-05-20 | PXD025491 | Pride

Expression data of osimertinib tolerant H1975 cells

Project description:Even after osimertinib is administered to lung adenocarcinomas with EGFR mutations, there are a few cells which survive, and these tolerant cells are considered to be the source of later recurrence. We used microarray analysis to explore the mechanism behind the tolerance to osimertinib in lung adenocarcinoma cells with EGFR mutations.

2022-04-16 | GSE200893 | GEO

MUSASHI-2 RNA binding protein confers resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor Osimertinib in lung adenocarcinoma

Project description:Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, due to the acquired resistance to EGFR-TKIs, even third generation Osimertinib, the patients suffer poor prognosis. The resistance mechanisms are still not fully understood. Here, we demonstrate that increased expression of MUSASHI-2 (MSI2), an RNA binding protein, is novel mechanisms for resistance to EGFR-TKIs. We found that after long-exposure of gefitinib, the first generation EGFR-TKI, lung cancer cells harboring the EGFR-TKI-sensitive mutations became resistant to not only gefitinib but also Osimertinib. Although other mutations in EGFR were not found, expression levels of Nanog, a stemness core protein, and activities of aldehyde dehydrogenase (ALDH) were increased, suggesting that cancer stem-like properties were increased. Transcriptome analysis revealed that MSI2 was among the top list of the stemness-related genes upregulated in the EGFR-TKI-resistant cells. Knockdown of MSI2 reduced cancer stem-like properties, including expression levels of Nanog a core stemness factor. We demonstrate that knockdown of MSI2 restored sensitivity to Osimertinib or gefitinib in the EGFR-TKI-resistant cells to the similar levels of the parental cells in vitro. RNA immunoprecipitation (RIP) assay revealed that antibodies against MSI2 bound to Nanog mRNA, suggesting that MSI2 increases Nanog expression by binding to Nanog mRNA. Moreover, overexpression of MSI2 or Nanog conferred resistance to Osimertinib or gefitinib in parental cells. Finally, knockdown of MSI2 greatly increased sensitivity to Osimertinib in vivo. Collectively, our findings provide proof-of-principle that targeting MSI2-Nanog axis in combination with EGFR-TKIs would effectively prevent emergence of acquired resistance.

2021-08-27 | GSE168280 | GEO

Expression data of osimertinib tolerant PC-9 cells

2022-04-16 | GSE200894 | GEO